|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1980-2-15
|
|
pubmed:abstractText |
The effect of high-dose medroxyprogesterone acetate (MPA, 250 mg intramuscularly for six days) on hepatic drug-metabolism and liver function was investigated in eleven females with endometrial carcinoma. Antipyrine plasma clearance, an index of hepatic drug-metabolizing ability, improved significantly during this treatment, and the serum total bilirubin level was lowered, whereas other liver function tests, including alkaline phosphatase, and albumin values in the serum, remained unchanged. The results demonstrate that therapy with MPA has an inducing effect on hepatic enzyme activity and antipyrine metabolism. The findings may be of importance when prescribing drugs for females receiving large doses of MPA.
|
|
pubmed:keyword |
http://linkedlifedata.com/resource/pubmed/keyword/Biology,
http://linkedlifedata.com/resource/pubmed/keyword/Cancer,
http://linkedlifedata.com/resource/pubmed/keyword/Contraception,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents...,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents, Female--side...,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents...,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents...,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents...,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents...,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive...,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents--side effects,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents--therapeutic use,
http://linkedlifedata.com/resource/pubmed/keyword/Diseases,
http://linkedlifedata.com/resource/pubmed/keyword/Endometrial Cancer,
http://linkedlifedata.com/resource/pubmed/keyword/Family Planning,
http://linkedlifedata.com/resource/pubmed/keyword/Hepatic Effects,
http://linkedlifedata.com/resource/pubmed/keyword/Injectables,
http://linkedlifedata.com/resource/pubmed/keyword/Medroxyprogesterone...,
http://linkedlifedata.com/resource/pubmed/keyword/Medroxyprogesterone Acetate--side...,
http://linkedlifedata.com/resource/pubmed/keyword/Medroxyprogesterone...,
http://linkedlifedata.com/resource/pubmed/keyword/Neoplasms,
http://linkedlifedata.com/resource/pubmed/keyword/Physiology,
http://linkedlifedata.com/resource/pubmed/keyword/Prospective Studies,
http://linkedlifedata.com/resource/pubmed/keyword/Research Methodology,
http://linkedlifedata.com/resource/pubmed/keyword/Studies
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0300-0893
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
31
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
135-8
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:otherAbstract |
PIP: The effects of high doses of medroxyprogesterone acetate (MPA) on liver metabolism were investigated by determining the plasma antipyrine clearance rates for a group of 11 patients with endometrial cancer both before and during use of MPA in therapy. MPA dosage was 250 mg, intramuscularly, for 6 days. The antipyrine half-life was prolonged in 4 patients. MPA treatment had an inducing effect on antipyrine metabolism; the plasma half-life of the drug was shortened and apparent clearance rate increased; however, no change occurred in the apparent volume of distribution of the drug. Significant decreases in bilirubin were also seen (P .01), but no other liver function tests showed significant differences. When the patients were divided into 2 groups according to age over or under 60 years, there was a significant difference (P .05), with the younger group having a half-life of 8.1 hours and the older group evincing a half-life of 13.6. These half-lives were reduced by MPA treatment to 7.5 and 11 hours, respectively. The results indicate that MPA therapy has an inducing effect on hepatic enzyme activity and antipyrine metabolism.
|
|
pubmed:meshHeading |
pubmed-meshheading:508896-Adult,
pubmed-meshheading:508896-Aged,
pubmed-meshheading:508896-Aging,
pubmed-meshheading:508896-Antipyrine,
pubmed-meshheading:508896-Female,
pubmed-meshheading:508896-Half-Life,
pubmed-meshheading:508896-Humans,
pubmed-meshheading:508896-Liver,
pubmed-meshheading:508896-Liver Function Tests,
pubmed-meshheading:508896-Medroxyprogesterone,
pubmed-meshheading:508896-Middle Aged,
pubmed-meshheading:508896-Time Factors,
pubmed-meshheading:508896-Uterine Neoplasms
|
|
pubmed:year |
1979
|
|
pubmed:articleTitle |
Antipyrine metabolism and liver function in patients treated with high-dose medroxyprogesterone.
|
|
pubmed:publicationType |
Journal Article
|
